Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial

a study on Thoracic Diseases Postoperative Pain Opioid Use

Summary

Eligibility
for people ages 18 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
Johannes Kratz
Photo of Johannes Kratz
Johannes Kratz

Description

Summary

The Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial is a single center, double-blind, randomized, active-comparator controlled clinical trial to assess the analgesic efficacy of intercostal nerve block by Liposomal Bupivacaine versus Standard Bupivacaine in subjects undergoing lung resection by robotic or video-assisted thoracoscopic surgery.

Official Title

Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial - Liposomal Bupivacaine Versus Standard Bupivacaine

Keywords

Thoracic Diseases Postoperative Pain Opioid Use Liposomal Bupivacaine Intercostal Nerve Block Minimally Invasive Thoracic Surgery Bupivacaine

Eligibility

You can join if…

Open to people ages 18 years and up

  • Robotic or Video-Assisted Lung Resection for All Indications

You CAN'T join if...

  • Additional Thoracic Procedures (beyond lung resection and mediastinal lymphadenectomy)
  • Extra-Thoracic Procedures
  • Hypersensitivity to Amide Local Analgesia
  • Cardiac Conduction Abnormalities
  • Hepatic Dysfunction
  • Preoperative Neuropathic Pain and/or Preoperative Daily Opioid Usage

Location

  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Johannes Kratz
    Johannes R. Kratz, M.D. is Director of Minimally Invasive and Robotic Thoracic Surgery and holds the Van Auken Endowed Chair in Thoracic Oncology. Kratz graduated magna cum laude from Harvard Medical School and holds a Masters in Philosophy from Stanford.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT03508830
Phase
Phase 3
Study Type
Interventional
Last Updated
Contact us about this trial